As of June 30, 2026, Chugai Pharmaceutical Co., Ltd. carries a market capitalization of 1.34T, placing it among publicly traded companies globally. Its enterprise value stands at 1.24T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.34T |
| Enterprise Value | 1.24T |
Chugai Pharmaceutical Co., Ltd.'s next confirmed earnings release is scheduled for October 27, 2026.
| Earnings Date | 10/27/2026 |
As of June 30, 2026, Chugai Pharmaceutical Co., Ltd. has 1.65B shares outstanding.
| Shares Outstanding | 1.65B |
These figures are as of June 30, 2026.
| PB Ratio | 6.16 |
| P/TBV Ratio | 6.34 |
As of June 30, 2026, Chugai Pharmaceutical Co., Ltd. maintains a current ratio of 4.35, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.35 |
| Quick Ratio | 2.45 |
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 7,848.50 |
As of the close on September 3, 2026, Chugai Pharmaceutical Co., Ltd.'s stock has declined approximately 6.74% over the past 52 weeks.
| 52-Week Price Change | -6.74% |
These figures are as of June 30, 2026. Total book value stands at 217.92B, with working capital of 141.00B providing operational flexibility.
| Cash & Cash Equivalents | 103.45B |
| Net Debt | -41.96B |
| Equity (Book Value) | 217.92B |
| Book Value Per Share | 132.43 |
| Working Capital | 141.00B |
Chugai Pharmaceutical Co., Ltd.'s most recent stock split took place on June 29, 2020 with a 1:3 split ratio.
| Last Split Date | 6/29/2020 |
| Split Ratio | 1:3 |
Already premium?